Business Description
Bide Pharmatech Co Ltd
ISIN : CNE100005NV3
Share Class Description:
SHSE:688073: Class ATotal Employee Number:
734Compare
Compare
Traded in other countries / regions
688073.China Index Membership
SSE Composite Index IPO Date
2022-10-11Description
Bide Pharmatech Co Ltd is engaged in the research and development, design, production and sales of drug molecular building blocks.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 7.96 | |||||
Equity-to-Asset | 0.83 | |||||
Debt-to-Equity | 0.06 | |||||
Debt-to-EBITDA | 0.62 | |||||
Interest Coverage | 57.71 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 7.78 | |||||
Beneish M-Score | -2.57 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 10.1 | |||||
3-Year EBITDA Growth Rate | 0.5 | |||||
3-Year EPS without NRI Growth Rate | -6.7 | |||||
3-Year Book Growth Rate | -0.5 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 39.9 | |||||
9-Day RSI | 40.97 | |||||
14-Day RSI | 42.75 | |||||
3-1 Month Momentum % | -14.18 | |||||
6-1 Month Momentum % | -11.98 | |||||
12-1 Month Momentum % | -8.08 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.43 | |||||
Quick Ratio | 4.37 | |||||
Cash Ratio | 3.41 | |||||
Days Inventory | 447.91 | |||||
Days Sales Outstanding | 68.44 | |||||
Days Payable | 105.53 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 2.5 | |||||
Dividend Payout Ratio | 0.4 | |||||
Forward Dividend Yield % | 2.5 | |||||
5-Year Yield-on-Cost % | 2.29 | |||||
Shareholder Yield % | 1.37 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 45.62 | |||||
Operating Margin % | 19.88 | |||||
Net Margin % | 12.43 | |||||
EBITDA Margin % | 16.15 | |||||
FCF Margin % | 2.63 | |||||
OCF Margin % | 4.49 | |||||
ROE % | 8.29 | |||||
ROA % | 6.55 | |||||
ROIC % | 16.53 | |||||
3-Year ROIIC % | 8.09 | |||||
ROC (Joel Greenblatt) % | 21.6 | |||||
ROCE % | 10.38 | |||||
Years of Profitability over Past 10-Year | 6 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 26.24 | |||||
Forward PE Ratio | 23.28 | |||||
PE Ratio without NRI | 22.67 | |||||
Price-to-Owner-Earnings | 35.96 | |||||
PEG Ratio | 2.14 | |||||
PS Ratio | 3.24 | |||||
PB Ratio | 2.19 | |||||
Price-to-Tangible-Book | 2.21 | |||||
Price-to-Free-Cash-Flow | 123.83 | |||||
Price-to-Operating-Cash-Flow | 72.47 | |||||
EV-to-EBIT | 17.08 | |||||
EV-to-EBITDA | 17.08 | |||||
EV-to-Revenue | 2.76 | |||||
EV-to-FCF | 104.85 | |||||
Price-to-GF-Value | 0.75 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.78 | |||||
Price-to-Graham-Number | 1.49 | |||||
| Price-to-Net-Current-Asset-Value | 2.42 | |||||
| Price-to-Net-Cash | 7.24 | |||||
Earnings Yield (Greenblatt) % | 5.85 | |||||
FCF Yield % | 0.77 | |||||
Forward Rate of Return (Yacktman) % | 12.5 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bide Pharmatech Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 1,350.714 | ||
| EPS (TTM) (Â¥) | 1.93 | ||
| Beta | 1.6996 | ||
| 3-Year Sharpe Ratio | -0.09 | ||
| 3-Year Sortino Ratio | -0.14 | ||
| Volatility % | 41.29 | ||
| 14-Day RSI | 42.75 | ||
| 14-Day ATR (Â¥) | 3.480351 | ||
| 20-Day SMA (Â¥) | 50.2535 | ||
| 12-1 Month Momentum % | -8.08 | ||
| 52-Week Range (Â¥) | 43.21 - 82.88 | ||
| Shares Outstanding (Mil) | 90.88 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bide Pharmatech Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bide Pharmatech Co Ltd Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| CNY 1.160000 Cash Dividend | 2026-06-10 | 47.00 (+0.90%) | ||
| CNY 0.900000 Cash Dividend | 2025-06-09 | 44.88 (-4.00%) | ||
| 1.4:1 Stock Split | 2023-05-25 | 92.03 (-0.15%) |
Show
Entries
Bide Pharmatech Co Ltd Frequently Asked Questions
What is Bide Pharmatech Co Ltd(SHSE:688073)'s stock price today?
The current price of SHSE:688073 is ¥50.65. The 52 week high of SHSE:688073 is ¥82.88 and 52 week low is ¥43.21.
When is next earnings date of Bide Pharmatech Co Ltd(SHSE:688073)?
The next earnings date of Bide Pharmatech Co Ltd(SHSE:688073) is .
Does Bide Pharmatech Co Ltd(SHSE:688073) pay dividends? If so, how much?
The Dividend Yield %  of Bide Pharmatech Co Ltd(SHSE:688073) is 2.5% (As of Today), Highest Dividend Payout Ratio of Bide Pharmatech Co Ltd(SHSE:688073) was 1.14. The lowest was 0.4. And the median was 0.77. The  Forward Dividend Yield % of Bide Pharmatech Co Ltd(SHSE:688073) is 2.5%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Bide Pharmatech Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers